

Major depressive disorder (MDD) treatment: from biological basis to patient reality

Scientific Committee: Siegfried Kasper, Austria; Daniel Souery, Belgium

Chair: Siegfried Kasper, Austria

Co-chair: Gitte Moos Knudsen, Denmark

Sunday 8th September, 17:30–19:00

Bella Center Copenhagen, Room C4
Copenhagen, Denmark

17:30 Welcome and introduction *Siegfried Kasper, Austria; Gitte Moos Knudsen, Denmark*

17:40 The neurons: the pathway to change *Christine Denny, USA*

18:05 Accelerating the treatment pathway in MDD *Siegfried Kasper, Austria*

18:30 MDD speaking: integrating patient experiences into clinical decision-making
Daniel Souery, Belgium

18:55 Closing remarks *Gitte Moos Knudsen, Denmark*

Throughout this symposium, the multidisciplinary faculty will provide the perspective of the basic scientist, clinician and patient on each of the topics presented.

With educational financial support provided by
Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA.

Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, Belgium

Date of preparation: June 2019
EM-08330



The European Accreditation Committee in CNS (EACIC) has granted 2 CME credits to this satellite symposium. To obtain your CME credits, fill out the evaluation form on www.eacic.eu.



PHARMACEUTICAL COMPANIES OF **Johnson & Johnson**

Donna Williams, *Enticement*

An autistic artist, author and renowned autism advocate,
Donna passed away from cancer in 2017.

**Satellite symposium
on the occasion of the
32nd ECNP Congress**

Copenhagen, Denmark
7th–10th September 2019